Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject's parent(s)/Legally Acceptable Representative(s) and subjects who the investigator believes can and are willing to comply with the requirements of the protocol.~* A male or female between 10 and 15 years of age at the time of booster vaccination.~* Prior to protocol amendment 2, subjects who have previously received 5 doses of diphtheria-tetanus-pertussis vaccine (whole cell/acellular \[w/a\]) as part of primary and booster vaccination, in line with local recommendations.~* After protocol amendment 2, subjects who have previously received 6 doses of either DT(P) (w/a)/ dTpa vaccine as part of primary and booster vaccination, in line with local recommendations.~* Healthy subjects as determined by the investigator based on medical history and clinical examination before entering into the study.~* Written informed consent to be obtained before study entry from the parent(s)/ Legally Acceptable Representative(s) of the subject.~* Written informed assent to be obtained from the subject in addition to the informed consent signed by the parent(s)/ Legally Acceptable Representative(s), if required by local regulations.~* Female subjects of non-childbearing potential may be enrolled in the study.~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~  * has a negative pregnancy test on the day of vaccination,~ * if sexually active, has practiced adequate contraception for 30 days prior to vaccination, and has agreed to continue adequate contraception during the entire treatment period and for 2 months after booster vaccination.~Exclusion Criteria:~* Child in care.~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the booster dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.~* Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the booster dose of vaccine - with the exception of influenza vaccine which is allowed up to 7 days before the study vaccine dose, or planned in the period ≥ 7 days after the study vaccine dose.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* A history of previous or intercurrent diphtheria, tetanus or pertussis disease.~* A history of vaccination against these diseases since the 5th or the 6th dose of DT(P)/dT(pa). For subjects who have received the 6th dose of the diphtheria, tetanus and/or pertussis containing vaccine, the interval between the last DT(P)/dT(pa) vaccination and the administration of the study vaccine should be at least 18 months.~* Occurrence of any of the following adverse event after a previous administration of a Boostrix vaccine :~  * known hypersensitivity to any component of the vaccine, or have shown signs of hypersensitivity after previous administration of diphtheria, tetanus or pertussis vaccines,~ * encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine,~ * transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.~* Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.~* Acute disease and/or fever at the time of enrolment.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions, if applicable.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- BOOSTRIX NEW GROUP (Type: EXPERIMENTAL): Subjects, aged 10 to 15 years, received one dose of Boostrix™ vaccine administered using a new syringe presentation (prefilled syringes from a different manufacturer) in the deltoid of the non-dominant arm, at Day 0.
- BOOSTRIX PREV GROUP (Type: ACTIVE_COMPARATOR): Subjects, aged 10 to 15 years, received one dose of Boostrix™ vaccine administered using a previous syringe presentation (single dose vial or a prefilled disposable syringe without a needle) in the deltoid of the non-dominant arm, at Day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete